Company intelligence / Profile preview
Cantargia AB
Lund, Skåne, Swedencantargia.com ↗
- Ownership
- Public · CANTA
- Employees
- ~22
- Development stage
- Phase 2
01
Overview
Cantargia’s lead asset nadunolimab (CAN04) is in Phase II trials for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. CAN10 entered clinical development in 2023 targeting autoimmune/inflammatory indications. Recent results show positive safety/biomarker data for CAN10 and efficacy signals in multiple cancers with nadunolimab combined with chemotherapy.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Patheon Biologics B.V. & BioWa Inc. – manufacturing/production of CAN04GEICAM – Spanish breast cancer group collaboration
04
Financials
- Market cap
- $46.1M
- Total revenue
- $32.1M
- Enterprise value
- $23.6M
Beyond the preview
Go deeper on Cantargia AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cantargia AB.